Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Boston, MA - Christopher Paul German, Corporate Controller & CAO at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), sold 1,500 shares of common stock on August 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $95.0, for a total transaction value of $142,500.
On the same day, German also exercised options to acquire a total of 1,500 shares of Rhythm Pharmaceuticals common stock. These transactions involved two separate option grants. The first grant was for 1,000 shares at an exercise price of $17.97, and the second was for 500 shares at an exercise price of $49.23. The total value of these transactions was $42,585 with prices ranging from $17.97 to $49.23.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025. InvestingPro analysis indicates the stock has shown significant price volatility, with technical indicators suggesting overbought conditions. Subscribers can access 12 additional ProTips and comprehensive valuation metrics for RYTM through the platform’s detailed research reports.
In other recent news, Rhythm Pharmaceuticals reported its second-quarter 2025 earnings, revealing a revenue of $48.5 million, which surpassed the forecast of $43.75 million. This represents a 29% increase quarter-over-quarter, highlighting strong performance in sales of its product, Imcivree. Despite the impressive revenue figures, the company posted a wider-than-expected loss per share of -$0.75, missing analyst expectations of -$0.67. Following these results, several analyst firms have adjusted their price targets for the company. H.C. Wainwright raised its price target to $100 from $80, maintaining a Buy rating. TD Cowen also increased its price target to $110 from $85, citing the strong revenue performance. Additionally, Citizens JMP raised its price target to $135 from $130, maintaining a Market Outperform rating and noting the company’s efforts to expand its pipeline opportunities. Rhythm Pharmaceuticals remains on track to submit regulatory applications for setmelanotide for hypothalamic obesity in the U.S. and EU this quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.